These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 34162404)

  • 1. A precision medicine classification for treatment of acute myeloid leukemia in older patients.
    Mims AS; Kohlschmidt J; Borate U; Blachly JS; Orwick S; Eisfeld AK; Papaioannou D; Nicolet D; Mrόzek K; Stein E; Bhatnagar B; Stone RM; Kolitz JE; Wang ES; Powell BL; Burd A; Levine RL; Druker BJ; Bloomfield CD; Byrd JC
    J Hematol Oncol; 2021 Jun; 14(1):96. PubMed ID: 34162404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
    Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
    Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia.
    Fobare S; Kohlschmidt J; Ozer HG; Mrózek K; Nicolet D; Mims AS; Garzon R; Blachly JS; Orwick S; Carroll AJ; Stone RM; Wang ES; Kolitz JE; Powell BL; Oakes CC; Eisfeld AK; Hertlein E; Byrd JC
    Blood Adv; 2022 Mar; 6(5):1371-1380. PubMed ID: 34847232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
    El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
    Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
    Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of autologous hematopoietic stem cell transplantation according to the NPM1/FLT3-ITD molecular status for cytogenetically normal AML patients: a GOELAMS study.
    Guièze R; Cornillet-Lefebvre P; Lioure B; Blanchet O; Pigneux A; Recher C; Bonmati C; Fegueux N; Bulabois CE; Bouscary D; Vey N; Delain M; Turlure P; Himberlin C; Harousseau JL; Dreyfus F; Béné MC; Ifrah N; Chevallier P;
    Am J Hematol; 2012 Dec; 87(12):1052-6. PubMed ID: 22911473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia.
    How J; Sykes J; Gupta V; Yee KW; Schimmer AD; Schuh AC; Minden MD; Kamel-Reid S; Brandwein JM
    Cancer; 2012 Dec; 118(24):6110-7. PubMed ID: 22736495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
    Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
    J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.
    Burd A; Levine RL; Ruppert AS; Mims AS; Borate U; Stein EM; Patel P; Baer MR; Stock W; Deininger M; Blum W; Schiller G; Olin R; Litzow M; Foran J; Lin TL; Ball B; Boyiadzis M; Traer E; Odenike O; Arellano M; Walker A; Duong VH; Kovacsovics T; Collins R; Shoben AB; Heerema NA; Foster MC; Vergilio JA; Brennan T; Vietz C; Severson E; Miller M; Rosenberg L; Marcus S; Yocum A; Chen T; Stefanos M; Druker B; Byrd JC
    Nat Med; 2020 Dec; 26(12):1852-1858. PubMed ID: 33106665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations.
    Loghavi S; Zuo Z; Ravandi F; Kantarjian HM; Bueso-Ramos C; Zhang L; Singh RR; Patel KP; Medeiros LJ; Stingo F; Routbort M; Cortes J; Luthra R; Khoury JD
    J Hematol Oncol; 2014 Oct; 7():74. PubMed ID: 25281355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3-ITD AML.
    Buelow DR; Pounds SB; Wang YD; Shi L; Li Y; Finkelstein D; Shurtleff S; Neale G; Inaba H; Ribeiro RC; Palumbo R; Garrison D; Orwick SJ; Blachly JS; Kroll K; Byrd JC; Gruber TA; Rubnitz JE; Baker SD
    Clin Transl Sci; 2019 Nov; 12(6):641-647. PubMed ID: 31350825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.
    Daver N; Liu Dumlao T; Ravandi F; Pierce S; Borthakur G; Pemmaraju N; Nazha A; Faderl S; Jabbour E; Garcia-Manero G; Cortes J; Kantarjian H; Quintás-Cardama A
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):435-40. PubMed ID: 23763915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower frequency of NPM1 and FLT3-ITD mutations in a South African adult de novo AML cohort.
    Marshall RC; Tlagadi A; Bronze M; Kana V; Naidoo S; Wiggill TM; Carmona SC
    Int J Lab Hematol; 2014 Dec; 36(6):656-64. PubMed ID: 24666762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
    Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
    Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes.
    Boddu PC; Kadia TM; Garcia-Manero G; Cortes J; Alfayez M; Borthakur G; Konopleva M; Jabbour EJ; Daver NG; DiNardo CD; Naqvi K; Yilmaz M; Short NJ; Pierce S; Kantarjian HM; Ravandi F
    Cancer; 2019 Apr; 125(7):1091-1100. PubMed ID: 30521114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapeutic Resistance in Egyptian Acute Myeloid Leukemia Patients.
    Kassem NM; Medhat N; Kassem HA; El-Desouky MA
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2421-2427. PubMed ID: 31450916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia.
    Scholl S; Theuer C; Scheble V; Kunert C; Heller A; Mügge LO; Fricke HJ; Höffken K; Wedding U
    Eur J Haematol; 2008 Mar; 80(3):208-15. PubMed ID: 18081718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Detection of NPM1, FLT3 and C-KIT mutations in acute myeloid leukemia and their prognostic analysis].
    Li L; Lyu XD; Mi RH; Ding J; Chen L; Wang Q; Yin QS; Hu JY; Fan RH; Wei XD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):601-6. PubMed ID: 23815906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.